Abstract
Comparative molecular field analysis (CoMFA) was carried out on Carbonic anhydrase inhibitor hCA IX- tumor-associated (Hypoxia). Database contains a series of aromatic benzene sulfonamides incorporating 1, 3, 5-triazine moieties derivative. This study correlates the inhibitory activities of structurally related 1, 3, 5-triazine moiety derivatives derived to Tripos standard in CoMFA. The data base alignment conformation yielded good predictive CoMFA model (r2cv = 0.82, F-value = 460.320, r2pred = 0.787 with five components). The contour maps obtained from 3D - QSAR studies were appraised for the activity trends of the molecules analyzed. The result indicates that the steric and electrostatic features play a significant role in the carbonic anhydrase inhibition activity and potency of these compounds. The data generated from the present study can be used as putative pharmacophore in the design of novel, potent and selective hCA IX inhibitors.
Keywords: Carbonic anhydrase inhibitor, CoMFA, 3D-QSAR, hCA IX, 1,3,5-triazine, Candida albicans, conformation, a-CA isozymes, pharmacophore, mitochondrial forms, tumor, Escherichia coli, ureagenesis, tumor microenvironment
Letters in Drug Design & Discovery
Title: A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX-Tumor-Associated (Hypoxia)
Volume: 8 Issue: 9
Author(s): Shalini Singh
Affiliation:
Keywords: Carbonic anhydrase inhibitor, CoMFA, 3D-QSAR, hCA IX, 1,3,5-triazine, Candida albicans, conformation, a-CA isozymes, pharmacophore, mitochondrial forms, tumor, Escherichia coli, ureagenesis, tumor microenvironment
Abstract: Comparative molecular field analysis (CoMFA) was carried out on Carbonic anhydrase inhibitor hCA IX- tumor-associated (Hypoxia). Database contains a series of aromatic benzene sulfonamides incorporating 1, 3, 5-triazine moieties derivative. This study correlates the inhibitory activities of structurally related 1, 3, 5-triazine moiety derivatives derived to Tripos standard in CoMFA. The data base alignment conformation yielded good predictive CoMFA model (r2cv = 0.82, F-value = 460.320, r2pred = 0.787 with five components). The contour maps obtained from 3D - QSAR studies were appraised for the activity trends of the molecules analyzed. The result indicates that the steric and electrostatic features play a significant role in the carbonic anhydrase inhibition activity and potency of these compounds. The data generated from the present study can be used as putative pharmacophore in the design of novel, potent and selective hCA IX inhibitors.
Export Options
About this article
Cite this article as:
Singh Shalini, A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX-Tumor-Associated (Hypoxia), Letters in Drug Design & Discovery 2011; 8 (9) . https://dx.doi.org/10.2174/157018011797200777
DOI https://dx.doi.org/10.2174/157018011797200777 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches
Current Pharmaceutical Design Recent Approaches and Success of Liposome-Based Nano Drug Carriers for the Treatment of Brain Tumor
Current Drug Delivery Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Telomeric G-Quadruplex Architecture and Interactions with Potential Drugs
Current Pharmaceutical Design Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Tumour Gene Therapy Monitoring Using Magnetic Resonance Imaging and Spectroscopy
Current Gene Therapy New Insights into the Chemistry and Antioxidant Activity of Coumarins
Current Topics in Medicinal Chemistry Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Monoclonal Antibodies in the Management of Solid Tumors
Current Topics in Medicinal Chemistry Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Towards More Successful Gene Therapy Clinical Trials for β-Thalassemia
Current Molecular Medicine Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors
Current Topics in Medicinal Chemistry TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry